M2137
N-Methyl-DL-aspartic acid
Sinonimo/i:
(±)-2-(Methylamino)succinic acid, NMA
Autenticati per visualizzare i prezzi organizzativi e contrattuali.
Scegli un formato
Cambia visualizzazione
| Taglio della confezione | SKU | Disponibilità | Prezzo |
|---|
Informazioni su questo articolo
Formula condensata:
HOCOCH2CH(NHCH3)COOH
Numero CAS:
Peso molecolare:
147.13
PubChem Substance ID:
UNSPSC Code:
12352200
Beilstein/REAXYS Number:
1724430
MDL number:
Prezzi e disponibilità al momento non sono disponibili
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutartiassay
≥98% (TLC)
form
powder
color
white
SMILES string
CNC(CC(O)=O)C(O)=O
InChI
1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)
InChI key
HOKKHZGPKSLGJE-UHFFFAOYSA-N
Biochem/physiol Actions
N-Methyl-DL-aspartic acid is a derivative of aspartic acid.
Classe di stoccaggio
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Scegli una delle versioni più recenti:
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
B Häggman-Henrikson et al.
Journal of oral rehabilitation, 44(10), 800-826 (2017-09-09)
This health technology assessment evaluated the efficacy of pharmacological treatment in patients with oro-facial pain. Randomised controlled trials were included if they reported pharmacological treatment in patients ≥18 years with chronic (≥3 months) oro-facial pain. Patients were divided into subgroups:
Yan Luo et al.
BMJ open, 8(12), e023222-e023222 (2018-12-12)
Depressive disorders are the most common, burdensome and costly mental disorders. Their treatments have developed through the past decades and we now have more than a dozen new generation antidepressants, while a series of guidelines have been published to provide
Andrea C Tricco et al.
BMC medicine, 14(1), 216-216 (2016-12-23)
Although serotonin (5-HT3) receptor antagonists are effective in reducing nausea and vomiting, they may be associated with increased cardiac risk. Our objective was to examine the comparative safety and effectiveness of 5-HT3 receptor antagonists (e.g., dolasetron, granisetron, ondansetron, palonosetron, tropisetron)